Daewoong Pharma Takes P-CAB Drug Fexuclue Into Indonesia
Daewoong Pharmaceutical has launched its homegrown gastroesophageal reflux disease (GERD) treatment Fexuclue in Indonesia, opening another front in the company’s push to expand its gastrointestinal drug business across Southeast Asia.Fexuclue 40mg, whose active ingredient is fexuprazan hydrochloride
Daewoong Pharmaceutical has introduced its GERD medication Fexuclue into the Indonesian market, furthering the company's ambition to extend its gastrointestinal drug portfolio throughout Southeast Asia. Fexuclue 40mg, which contains fexuprazan hydrochloride as its active ingredient, has received approval in Indonesia for addressing erosive GERD.
The company aims to bolster its prescription base by emphasizing Fexuclue's swift action, persistent acid suppression, and capability to address nighttime symptoms. The launch follows a rising demand for remedies targeting acid-related gastrointestinal disorders in Indonesia, a country with a population of around 280 million and the largest economy in Southeast Asia.
In 2025, Indonesia's anti-ulcer drug market had a value of approximately $164.3 million (235 billion won), growing at an average annual rate of 6.8% from 2023 to 2025. Although dominated by proton pump inhibitors (PPIs), the market is witnessing growth in the newer potassium-competitive acid blockers (P-CABs) category. The P-CAB market has expanded eightfold in the past two years, demonstrating increasing interest in the novel class of acid-suppressing treatments.
Globally, the P-CAB market is projected to grow from about 1.55 trillion won in 2025 to around 1.88 trillion won by 2030, according to BCC Research. Daewoong is also pursuing more clinical evidence to expand Fexuclue's applications in Indonesia and other markets. The company is conducting a multinational Phase 3 study in South Korea and Indonesia for a gastric ulcer indication, with the goal of expanding Fexuclue's potential prescription base.
The Indonesian debut is part of a larger international rollout of Fexuclue, which has been launched in 30 overseas markets and approved in 16 countries. The drug is currently available in eight countries, including Mexico, India, and the Philippines. Daewoong aims to capitalize on Indonesia's vast population, burgeoning gastrointestinal drug market, and early-stage P-CAB therapy expansion as a strategic base for its broader ASEAN strategy.
Written by urgent.news from Korea IT Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
